David Marek, Myovant

My­ovant beefs up da­ta pack­age in NDA #3, boost­ing its case for longterm dos­ing of Pfiz­er-part­nered re­l­u­golix

When Pfiz­er hand­ed over $650 mil­lion in cash to part­ner on My­ovant’s re­l­u­golix, the phar­ma gi­ant made clear that the deal — val­ued at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.